Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential
UMass Chan Affiliations
Department of Biochemistry and Molecular PharmacologyDocument Type
Journal ArticlePublication Date
2009-09-01Keywords
AnimalsAntineoplastic Agents
Antirheumatic Agents
Arthritis, Rheumatoid
Catalysis
Drug Design
*Drug Discovery
Enzyme Inhibitors
Humans
Hydrolases
Immunologic Factors
Isoenzymes
Models, Molecular
Molecular Structure
Multiple Sclerosis
Neoplasms
Protein Conformation
Structure-Activity Relationship
Protein Arginine Deiminase
Rheumatoid Arthritis
Multiple Sclerosis
Cancer
Treatment
Inhibitors
Biochemistry
Enzymes and Coenzymes
Medicinal-Pharmaceutical Chemistry
Therapeutics
Metadata
Show full item recordAbstract
The protein arginine deiminases (PADs), and in particular PAD4, have emerged as potential therapeutic targets for the treatment of rheumatoid arthritis (RA). In this review, evidence linking dysregulated PAD activity to the onset and progression of RA is presented, and the potential role of such aberrant activity in other human diseases, such as multiple sclerosis and cancer, is discussed. The known physiological roles of the PADs, particularly PAD4, and current knowledge regarding PAD structure, catalysis and inhibition are also described.Source
Curr Opin Drug Discov Devel. 2009 Sep;12(5):616-27.Permanent Link to this Item
http://hdl.handle.net/20.500.14038/50055Notes
At the time of publication, Paul Thompson was not yet affiliated with UMass Medical School.